文献速递消化道肿瘤放疗放疗物理与技术

食管癌肿瘤标记物用于量化放疗摆位误差与基线偏移

The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-11-05

结果显示植入安全,但标记物稳定性低于其他类型;远端食管标记物头脚方向分次间位移最大,软组织匹配较骨性解剖匹配可减小该方向外扩边界,分次内基线偏移对外扩边界计算影响较小。

要点

  • 食管癌金标记物植入安全,但稳定性低于其他类型标记物。
  • 远端食管标记物头脚方向分次间位移最大,软组织匹配可减小外扩边界。
  • 分次内基线偏移对外扩边界计算影响较小。

核心结论

  • 金标记物植入安全,但稳定性低于其他类型标记物。
  • 分次间位移在远端食管标记物头脚方向最大,软组织匹配较骨性解剖匹配可减小该方向外扩边界。
  • 分次内基线偏移对外扩边界计算影响较小。

研究设计与样本

  • 患者接受计划4D CT、每日治疗前CBCT及治疗后CBCT,至少5个分次。

主要发现

  • 骨性解剖匹配后,远端标记物分次间位移外扩边界为左右11.2 mm、头脚16.4 mm、前后8.2 mm。
  • 软组织匹配使远端标记物头脚方向外扩边界从16.4 mm降至10.5 mm。
  • 12枚远端标记物分次内平均位移为左右0.4 mm、头脚2.3 mm、前后0.7 mm。
  • 纳入分次内位移后,骨性解剖匹配下远端标记物外扩边界为左右12.8 mm、头脚17.3 mm、前后10.4 mm;软组织匹配下为左右12.4 mm、头脚11.4 mm、前后9.7 mm。

关键数值与推荐

  • 远端标记物骨性解剖匹配后分次间位移外扩边界:左右11.2 mm、头脚16.4 mm、前后8.2 mm。
  • 远端标记物软组织匹配后头脚方向外扩边界:10.5 mm。
  • 远端标记物分次内平均位移:左右0.4 mm、头脚2.3 mm、前后0.7 mm。
  • 纳入分次内位移后骨性解剖匹配外扩边界:左右12.8 mm、头脚17.3 mm、前后10.4 mm。
  • 纳入分次内位移后软组织匹配外扩边界:左右12.4 mm、头脚11.4 mm、前后9.7 mm。

临床怎么用

  • 食管癌放疗可考虑植入金标记物进行位置验证,但需注意其稳定性低于其他类型标记物。
  • 远端食管标记物头脚方向位移较大,建议采用软组织匹配以减小头脚方向外扩边界。
  • 分次内基线偏移对外扩边界影响较小,但仍需纳入边界计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To prospectively evaluate the feasibility of solid gold marker placement in oesophageal cancer patients and to quantify inter-fractional and intra-fractional (baseline shift) marker motion during radiation treatment. Radiotherapy target margins and matching strategies were investigated. MATERIALS/METHODS: Thirty-four markers were implanted by echo-endoscopy in 10 patients. Patients received a planning 4D CT, daily pre-treatment cone-beam CT (CBCT) and a post-treatment CBCT for at least five fractions. For fractions with both pre- and post-treatment CBCT, marker displacement between planning CT and pre-treatment CBCT (inter-fractional) and between pre-treatment and post-treatment CBCT (intra-fractional; only for fractions without rotational treatment couch correction) were calculated in left-right (LR), cranio-caudal (CC) and anterior-posterior (AP) direction after bony-anatomy and soft-tissue matching. Systematic/random setup errors were estimated; treatment margins were calculated. RESULTS: No serious adverse events occurred. Twenty-three (67.6%) markers were visible during radiotherapy (n = 3 middle oesophagus, n = 16 distal oesophagus, n = 4 proximal stomach). Margins for inter-fractional displacement after bony-anatomy match depended on the localisation of the primary tumour and were 11.2 mm (LR), 16.4 mm (CC) and 8.2 mm (AP) for distal markers. Soft-tissue matching reduced the CC margin for these markers (16.4 mm to 10.5 mm). The mean intra-fractional shift of 12 distal markers was 0.4 mm (LR), 2.3 mm (CC) and 0.7 mm (AP). Inclusion of this shift resulted in treatment margins for distal markers of 12.8 mm (LR), 17.3 mm (CC) and 10.4 mm (AP) after bony-anatomy matching and 12.4 mm (LR), 11.4 mm (CC) and 9.7 mm (AP) after soft-tissue matching. CONCLUSION: This study demonstrated that the implantation of gold markers was safe, albeit less stable compared to other marker types. Inter-fractional motion was largest cranio-caudally for markers in the distal oesophagus, which was reduced after soft-tissue compared to bony-anatomy matching. The impact of intra-fractional baseline shifts on margin calculation was rather small.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Thomas M, De Roover R, van der Merwe S, et al. The use of tumour markers in oesophageal cancer to quantify setup errors and baseline shifts during treatment. Clin Transl Radiat Oncol. 2020. PMID: 33251342. doi:10.1016/j.ctro.2020.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。